COMP <GO>
ICUI vs MRK // ENTERPRISE SCALE & MARKET CAP
ICU Medical Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: ICUI 2
— MRK 9
▲ ENTERPRISE SCALE & MARKET CAP LEADER: MRK
LAST: $168.65 (+1.36%) • MKT CAP: $4.22B
market-cap
$4.22B
LAST: $146.33 (+3.83%) • MKT CAP: $361.02B
market-cap
$361.02B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ICUI VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ICUI | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 36.80% | 74.80% | -38.00 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 1.00% | 20.70% | -19.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 46.6x | 15.3x | +31.30 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 2.18% | 3.42% | -1.24 | MRK | /fcf-yield <GO> |
| Operating Margin | 1.90% | 34.30% | -32.40 | MRK | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 28.10% | -28.10 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | -6.30% | 1.30% | -7.60 | MRK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.19 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | ICUI | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.5 | 51.7 | +4.80 | ICUI | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $4.22B | $361.02B | -$356.80B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ICUI REV | MRK REV | ICUI GROSS % | MRK GROSS % | ICUI FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.23B | $65.01B | 36.8% | 74.8% | $91.8M | $12.36B |
| FY 2024 | $2.38B | $64.17B | 34.6% | 76.3% | $124.7M | $18.10B |
| FY 2023 | $2.26B | $60.12B | — | — | $166.2M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ICUI // BETA —
MRK // BETA 0.92